نمایش پرونده ساده آیتم

dc.contributor.authorEsparvarinha, M
dc.contributor.authorNickho, H
dc.contributor.authorMohammadi, H
dc.contributor.authorAghebati-Maleki, L
dc.contributor.authorAbdolalizadeh, J
dc.contributor.authorMajidi, J
dc.date.accessioned2018-08-26T07:19:04Z
dc.date.available2018-08-26T07:19:04Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/45504
dc.description.abstractKappa (kappa) or lambda (lambda) free light chains (FLCs) are produced from B cells during immunoglobulin synthesis. FLCs have been shown to participate in several key processes of immune responses. They are necessary to adjust PMN functions and assist PMN pre-stimulation. Moreover, they cause mast cell degranulation which releases pro-inflammatory mediators and stimulates local inflammatory responses in some conditions such as inflammatory bowel disease (IBD). Having low molecular weights which may straightly be toxic to proximal tubule cells (PTCs), FLCs can also have an important role in renal diseases. In this review we have highlighted the involvement of light chains in the pathogenesis of some inflammatory diseases and discussed their potential to be the targets of therapeutic purposes. (C) 2017 Elsevier Masson SAS. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofBIOMEDICINE & PHARMACOTHERAPY
dc.subjectFree light chains
dc.subjectKidney disease
dc.subjectInflammatory disease
dc.titleThe role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases
dc.typeReview
dc.citation.volume91
dc.citation.spage632
dc.citation.epage644
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1016/j.biopha.2017.04.121


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم